Pacira ((PCRX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pacira Pharmaceuticals is conducting a Phase 2 clinical study titled ‘A Phase 2, Randomized, Open-Label, Two-Arm Study to Evaluate a Procedure for Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release (TCA-IR) in Subjects With Osteoarthritis of the Hip.’ The study aims to assess the effectiveness of an injection procedure using two different needle sizes in patients with hip osteoarthritis, highlighting its potential significance in improving treatment outcomes.
The study tests two interventions: ZILRETTA, an extended-release injectable suspension, and Triamcinolone Acetonide, an immediate-release formulation. Both are designed to alleviate symptoms of osteoarthritis in the hip.
This interventional study is randomized with a parallel assignment model, where participants are divided into two groups receiving either ZILRETTA or TCA-IR, with further subdivision based on needle gauge. The study is open-label, meaning no masking is involved, and its primary purpose is treatment.
The study began on May 7, 2025, with primary completion expected in the future. The latest update was submitted on September 10, 2025, indicating ongoing recruitment and study progress.
This study update could influence Pacira’s stock performance, as positive results may enhance investor confidence and market position, especially in comparison to competitors in the osteoarthritis treatment space.
The study is currently recruiting, with further details available on the ClinicalTrials portal.